

Hear from leading pharmaceutical, biotech companies and regulatory experts at RNA therapeutics 2021

SMi Reports: Innovations in technologies and applications of RNA-based medicine

LONDON, LONDON BRIDGE , UNITED KINGDOM, January 8, 2021 /EINPresswire.com/ -- We have witnessed significant growth and innovation in the [RNA](#) market. The 2-day agenda for the upcoming virtual conference will bring together expertise from individuals in multiple disciplines in the field and offer a series of presentations through which you will gain insights into the key drivers of this ever-growing industry.



Hear from leading pharmaceutical and biotech companies, regulatory experts and academia on a wide variety of topics. Furthermore, with increasing developments in RNA [therapeutics](#), this year's agenda will explore the growing potential of RNAi.

Download the brochure for a full agenda and speaker line-up here: www.therapeutics-rna.com/einpr5

Here are some topics covered on RNA Therapeutic Applications:

Novel Therapies for Inherited Retinal Diseases

- An overview of ProQR's RNA therapies platform
- Sepofarsen (QR-110) for Leber's Congenital Amaurosis (LCA10)
- QR-421a for Usher syndrome Exon 13
- QR-1123 for P23H autosomal dominant RP
- QR-504a for Fuchs Endothelial Corneal Dystrophy

Jennifer Plum, Vice President Medical Affairs, ProQR

Moving cardiovascular noncoding RNA therapeutics towards clinical reality

- Innovative approaches to discover noncoding RNAs in cardiovascular disease
- Testing noncoding RNAs in large animal models
- Design of adaptive clinical studies using noncoding RNA modulators

Thomas Thum, Director, Institute of Molecular and Translational Therapeutic Strategies,
Hannover Medical School

RNA immunotherapies: developing cancer vaccines against immunogenic neoantigens

- A collaboration with the aim to develop a new generation of cancer vaccines via RNA
- New developments in immunology have made immunotherapy of cancer a new treatment option
- An overview of the technology and potential for further oncology therapeutics

Wigard Kloosterman, CSO, Frame Therapeutics

Self-amplifying mRNA (SAM) vaccines

- Overview the principal and preclinical program of the GSK self-amplifying RNA program, illustrated by specific examples
- Update the progress on its technical development
- Potentially discuss the clinical POC of the platform

Dong Yu, Fellow, Senior Director, and Head, GSK Vaccines

Register today for only £499. Secure your spot here: www.therapeutics-rna.com/einpr5

Commercial rate £999 - Service providers and vendors to pharmaceutical and biotechnology companies

Proudly sponsored by: Thermo Fisher Scientific, eTheRNA immunotherapies & CAS Group

--- ENDS ---

Contact Information:

For media enquiries contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 / Email: hsidhu@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Jinna Sidhu

SMi Group
02078276088
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/534215123>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.